Grail sued over cancer trial as 3 law firms probe disclosures

A shareholder class action lawsuit was filed against Grail Inc. on June 8, alleging the company made false statements about the probability of achieving a statistically significant reduction in Stage III-IV cancers in its NHS-Galleri trial.

"The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding the probability of achieving the primary endpoint," Holzer & Holzer LLC, the firm that filed the complaint, said in a statement.

At least three law firms — Holzer & Holzer, Robbins Geller Rudman & Dowd LLP, and Robbins LLP — have announced investigations or class actions on behalf of Grail investors who purchased shares of the Nasdaq-listed company. The claims center on the NHS-Galleri trial, a study evaluating Grail's multi-cancer early detection blood test.

The lawsuit introduces legal uncertainty for Grail, which has staked its commercial future on the Galleri test's ability to detect early-stage cancers. A failure to meet the primary endpoint in the NHS-Galleri trial could undermine the test's clinical utility case and delay reimbursement decisions. Investors will watch for the company's next public statement on the trial data and any subsequent legal filings.

This article is for informational purposes only and does not constitute investment advice.